HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectidin) without compromising efficacy in a rat mammary carcinoma.

Abstract
ET-743, an experimental antitumor drug with promising activity in sarcoma, breast and ovarian carcinoma, is currently under phase 2 clinical evaluation. It is hepatotoxic in animals and patients. We tested the hypothesis that indole-3-carbinol (I3C), the hydrolysis product of glucosinolates occurring in cruciferous vegetables, may protect against ET-743-induced hepatotoxicity in the female Wistar rat, the animal species with the highest sensitivity toward the adverse hepatic effect of this drug. Hepatotoxicity was adjudged by measurement of plasma levels of bilirubin, alkaline phosphatase (ALP) and aspartate aminotransferase (AST) and by liver histopathology. The effect of I3C on the kinetics of ET-743 in rat plasma and liver was investigated by high-pressure liquid chromatography. The effect of I3C on the antitumor efficacy of ET-743 was explored in rats bearing the 13762 mammary carcinoma. ET-743 (40 microg/kg i.v.) alone caused an elevation of plasma bilirubin, ALP and AST levels and degeneration and patchy focal necrosis of bile duct epithelial cells. Addition of I3C to the diet (0.5%) for 6 days prior to ET-743 administration almost completely abolished manifestations of hepatotoxicity. In contrast, a dietary concentration of 0.1% I3C did not protect, nor did dietary diindolylmethane (0.2%), an acid-catalyzed condensation product of I3C. Ingestion by rats of I3C for 6 days prior to ET-743 (40 microg/kg i.v.) decreased plasma but not hepatic concentrations of ET-743 compared to animals that received ET-743 alone. I3C did not interfere with the antitumor efficacy of ET-743. The results suggest that ingestion of I3C may counteract the unwanted effect of ET-743 in the liver. I3C should be investigated as a hepatoprotectant in patients who receive ET-743 therapy.
AuthorsSarah Donald, Richard D Verschoyle, Peter Greaves, Tina Colombo, Massimo Zucchetti, Cristiano Falcioni, Marco Zaffaroni, Maurizio D'Incalci, Margaret M Manson, Jose Jimeno, William P Steward, Andreas J Gescher
JournalInternational journal of cancer (Int J Cancer) Vol. 111 Issue 6 Pg. 961-7 (Oct 10 2004) ISSN: 0020-7136 [Print] United States
PMID15300810 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents, Alkylating
  • Antioxidants
  • Dioxoles
  • Indoles
  • Isoquinolines
  • Tetrahydroisoquinolines
  • indole-3-carbinol
  • Trabectedin
Topics
  • Administration, Oral
  • Animals
  • Antineoplastic Agents, Alkylating (adverse effects, pharmacokinetics, therapeutic use)
  • Antioxidants (administration & dosage, pharmacology)
  • Chemoprevention
  • Diet
  • Dioxoles (adverse effects, pharmacokinetics, therapeutic use)
  • Female
  • Indoles (administration & dosage, pharmacology)
  • Isoquinolines (adverse effects, pharmacokinetics, therapeutic use)
  • Liver (drug effects, enzymology, pathology)
  • Mammary Neoplasms, Animal
  • Neoplasms, Experimental
  • Rats
  • Rats, Wistar
  • Tetrahydroisoquinolines
  • Trabectedin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: